Primary refractory and early-relapsed Hodgkin's lymphoma: Strategies for therapeutic targeting based on the tumour microenvironment

Journal of Pathology

Volumn 237, Issue 1, 2015, Pages 4-13

  Carbone, Antonino ^a   Gloghini, Annunziata ^b   Castagna, Luca ^c   Santoro, Armando ^c   Carlo Stella, Carmelo ^c,d  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

chemorefractoriness; early relapsed Hodgkin's lymphoma; Hodgkin Reed Sternberg cells; Hodgkin's lymphoma; Hodgkin's lymphoma microenvironment; microenvironment; refractory Hodgkin's lymphoma; signalling pathways; transcription factors; tumour microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; CD30 LIGAND; CD40 LIGAND; COLLAGEN TYPE 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN; TRANSCRIPTION FACTOR;

B LYMPHOCYTE; CANCER GROWTH; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; EPSTEIN BARR VIRUS INFECTION; HUMAN; LYMPH NODE BIOPSY; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; APOPTOSIS; CELL COMMUNICATION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HODGKIN DISEASE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RECURRENT DISEASE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL COMMUNICATION; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; RECURRENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR MICROENVIRONMENT;

EID: 84938955534     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4558     Document Type: Review

References (78)

1. Stein H, Delsol G, Pileri SA, et al., Classical Hodgkin lymphoma; introduction. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn, Swerdlow SH, Campo E, Harris NL, et al. (eds). IARC: Lyon, France, 2008; 326-329.
2. Hjalgrim H, Engels EA,. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence. J Intern Med 2008; 264: 537-548.
3. Poppema S, Delsol G, Pileri SA,. Nodular lymphocyte predominant Hodgkin lymphoma. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn, Swerdlow SH, Campo E, Harris NL, et al. (eds). IARC: Lyon, France, 2008; 323-325.
4. Foss HD, Reusch R, Demel G, et al., Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999; 94: 3108-3113.
5. Aldinucci D, Gloghini A, Pinto A, et al., The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010; 221: 248-263.
6. Liu Y, Sattarzadeh A, Diepstra A, et al., The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Semin Cancer Biol 2014; 24: 15-22.
7. Steidl C, Connors JM, Gascoyne RD,. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29: 1812-1826.
8. Santoro A, Bonadonna G, Valagussa P, et al., Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
9. Engert A, Plutschow A, Eich HT, et al., Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652.
10. Canellos GP, Rosenberg SA, Friedberg JW, et al., Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol 2014; 32: 163-168.
11. Linch DC, Winfield D, Goldstone AH, et al., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
12. Brice P, Divine M, Simon D, et al., Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol 1999; 10: 1485-1488.
13. Moskowitz CH, Nimer SD, Zelenetz AD, et al., A two-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
14. Schmitz N, Pfistner B, Sextro M, et al., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071.
15. Moskowitz CH, Kewalramani T, Nimer SD, et al., Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645-652.
16. Majhail NS, Weisdorf DJ, Defor TE, et al., Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transpl 2006; 12: 1065-1072.
17. Gopal AK, Metcalfe TL, Gooley TA, et al., High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer 2008; 113: 1344-1350.
18. Viviani S, Di Nicola M, Bonfante V, et al., Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leukemia Lymphoma 2010; 51: 1251-1259.
19. Younes A., Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology: The Education Program of the American Society of Hematology 2009: 507-519.
20. Canellos GP,. Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma-can they make one of medical oncology's chemotherapy success stories more successful? J Clin Oncol 2012; 30: 2171-2172.
21. Moskowitz AJ, Perales M-A, Kewalramani T, et al., Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin's lymphoma. Br J Haematol 2009; 146: 158-163.
22. Martinez C, Canals C, Sarina B, et al., Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013; 24: 2430-2434.
23. Arai S, Fanale M, DeVos S, et al., Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leukemia Lymphoma 2013; 54: 2531-2533.
24. Crump M., Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology:The Education Program of the American Society of Hematology 2008: 326-333.
25. Younes A., Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011; 8: 85-96.
26. Younes A, Bartlett NL, Leonard JP, et al., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821.
27. Younes A, Gopal AK, Smith SE, et al., Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-2189.
28. Ansell SM, Lesokhin AM, Borrello I, et al., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319.
29. Anastasia A, Carlo-Stella C, Corradini P, et al., Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol 2014; 166: 140-142.
30. Moskowitz AJ, Hamlin PA, Jr., Perales MA, et al., Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013; 31: 456-460.
31. Sarina B, Castagna L, Farina L, et al., Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671-3677.
32. Sureda A, Robinson S, Canals C, et al., Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455-462.
33. Corradini P, Sarina B, Farina L,. Allogeneic transplantation for Hodgkin's lymphoma. Br J Haematol 2011; 152: 261-272.
34. Robinson SP, Sureda A, Canals C, et al., Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230-238.
35. Armand P, Kim HT, Ho VT, et al., Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transpl 2008; 14: 418-425.
36. Corradini P, Dodero A, Farina L, et al., Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316-2323.
37. Ram R, Gooley TA, Maloney DG, et al., Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl 2011; 17: 1537-1545.
38. Kuppers R., The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
39. Cader FZ, Vockerodt M, Bose S, et al., The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood 2013; 122: 4237-4245.
40. Carbone A, Gloghini A,. Activated DDR1 increases RS cell survival. Blood 2013; 122: 4152-4154.
41. Steidl C, Lee T, Shah SP, et al., Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-885.
42. Germano G, Frapolli R, Belgiovine C, et al., Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013; 23: 249-262.
43. Steidl C, Shah SP, Woolcock BW, et al., MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471: 377-381.
44. Reichel J, Chadburn A, Rubinstein PG, et al., Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015; 125: 1061-1072.
45. Aldinucci D, Celegato M, Borghese C, et al., IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. Br J Haematol 2011; 152: 182-190.
46. Carbone A, Gloghini A, Gattei V, et al., Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780-789.
47. Carbone A, Gloghini A, Gruss HJ, et al., CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995; 147: 912-922.
48. Celegato M, Borghese C, Umezawa K, et al., The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma. Cancer Lett 2014; 349: 26-34.
49. Zheng B, Fiumara P, Li YV, et al., MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019-1027.
50. Kuppers R, Engert A, Hansmann ML,. Hodgkin lymphoma. J Clin Invest 2012; 122: 3439-3447.
51. Küppers R, Re D,. Nature of Reed-Sternberg and L&H cells, and their molecular biology in Hodgkin lymphoma. In Hodgkin Lymphoma, Hoppe RT, Mauch PM, Armitage JO, et al. (eds). Lippincott Williams & Wilkins: Philadelphia, 2007; 74-88.
52. Pasqualucci L, Dalla Favera R,. Molecular biology of lymphomas. In De Vita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 10th edn, De Vita VTJ, Lawrence TS, Rosemberg SA, (eds). Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, 2014; 1511-1525.
53. Steidl C, Diepstra A, Lee T, et al., Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 2012; 120: 3530-3540.
54. Tiacci E, Doring C, Brune V, et al., Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012; 120: 4609-4620.
55. Greaves P, Gribben JG,. Lymphoid neoplasia. Laser-capturing the essence of Hodgkin lymphoma. Blood 2012; 120: 4451-4452.
56. Oki Y, Neelapu SS, Fanale M, et al., Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol 2015: 169: 689-693.
57. Carlo-Stella C, Ricci F, Dalto S, et al., Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist 2015; 20: 323-328.
58. Younes A, Oki Y, Bociek RG, et al., Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011; 12: 1222-1228.
59. Younes A, Sureda A, Ben-Yehuda D, et al., Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012; 30: 2197-2203.
60. Johnston PB, Inwards DJ, Colgan JP, et al., A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320-324.
61. Guidetti A, Carlo-Stella C, Locatelli SL, et al., Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br J Haematol 2012; 158: 108-119.
62. Greenwald DR, Li H, Luger SM, et al., A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). J Hematol Oncol 2013; 6: 46.
63. Guidetti A, Carlo-Stella C, Locatelli SL, et al., Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. Clin Cancer Res 2014; 20: 5641-5651.
64. Fehniger TA, Larson S, Trinkaus K, et al., A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118: 5119-5125.
65. Corazzelli G, Angrilli F, D'Arco A, et al., Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol 2013; 160: 207-215.
66. Chen R, Palmer JM, Tsai NC, et al., Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transpl 2014; 20: 1864-1868.
67. Gopal AK, Ramchandren R, O'Connor OA, et al., Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120: 560-568.
68. Green MR, Rodig S, Juszczynski P, et al., Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 2012; 18: 1611-1618.
69. Esteller M., Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
70. Lane AA, Chabner BA,. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-5468.
71. Yoo CB, Jones PA,. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
72. Gloghini A, Buglio D, Khaskhely NM, et al., Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 2009; 147: 515-525.
73. Younes A, Pro B, Fayad L,. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006; 107: 1731-1732.
74. Younes A, Oki Y, McLaughlin P, et al., Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 2012; 119: 4123-4128.
75. Kasamon YL, Jacene HA, Gocke CD, et al., Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012; 119: 4129-4132.
76. Smith SM, Schoder H, Johnson JL, et al., The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leukemia Lymphoma 2013; 54: 1405-1410.
77. Locatelli SL, Cleris L, Stirparo GG, et al., BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia 2014; 28: 1861-1871.
78. Shi L, Chen S, Yang L, et al., The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 2013; 6: 74.